Evidence map›Paper›PMID 40757083›Full record

ReviewCureus2025

Flavoured Vaping Products in Tobacco Harm Reduction: A Regulatory Perspective.

Ian M Fearon, Matthew Stevenson, Thomas Nahde

Abstract readReview
In one paragraph

Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ian M FearonScientific Research, whatIF? Consulting Ltd., Harwell, GBR.
Matthew StevensonGroup Science and Regulatory Affairs, Imperial Brands PLC, Bristol, GBR.
Thomas NahdeGroup Science and Regulatory Affairs, Reemtsma Cigarettenfabriken GmbH, Hamburg, DEU.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reducing the harms associated with cigarette smoking is a global public health priority. Both the individual‑ and population‑level health impacts of smoking can be reduced by novel products which deliver nicotine, but the use of which decreases user exposure to the harmful chemical toxicants responsible for smoking‑related disease. Electronic vaping products (EVP) heat a flavoured liquid, most commonly containing nicotine, to generate an inhalable aerosol. Smokers who switch exclusively to using EVP reduce their exposure to the harmful toxicants found in cigarette smoke, and increasing evidence supports that EVP can help smokers quit smoking and support tobacco harm reduction (THR) efforts. However, concerns are being raised regarding the use of EVP among those for whom they are not intended, particularly youth, which could mitigate their THR potential. Some of this concern is attributed to the use of non‑tobacco flavours in EVP, and there have been many calls to ban the use of such flavours. The aim of this review is to examine the recent scientific literature concerning non‑tobacco flavours in EVP, focussing on the potential toxicological impact of these flavours, whether flavours affect abuse liability/dependence potential and whether they support switching away from cigarette smoking, unintended use of flavoured EVP, and the impact of existing bans and the effect of regulation. Overall, we find that non‑tobacco flavoured EVP are not of a greater risk to health and have no greater abuse liability than tobacco flavoured EVP. There is some evidence that flavoured EVP may support switching among adult smokers, while unintended use may be experimental and may not translate into long‑term use or act as a 'gateway' into smoking. Current flavour bans have been largely ineffective in modifying use behaviour and may have unintended consequences such as increasing smoking prevalence and promoting illicit trade. Overall, the population‑level THR benefit of flavoured EVP, in terms of reducing smoking rates, largely outweighs the risks associated with unintended use. Maintaining flavour diversity is an important consideration when putting in place regulatory frameworks that aim to maximise the switching benefit for adult smokers and improve overall population‑level public health.

Indexed as

e cigaretteselectronic vaping productsflavourspublic healthtobacco harm reduction

Identifiers

PMID40757083
PMCPMC12317776

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.